Interview: Immunocore Gets Ready To Go To Market
The first molecule from its collaboration with GSK has just gone into Phase I trials but Immunocore CEO Andrew Hotchkiss tells Scrip that the UK biotech unicorn is also preparing for the launch of its own lead candidate, IMCgp100 for uveal melanoma.
You may also be interested in...
A key figure in AstraZeneca’s resurgence, Jallal now leaves to head up a clinical-stage firm. She’s been an outspoken advocate for greater gender equity in biopharma leadership.
Oxford, UK-based Immunocore, which is developing immunotherapies against cancer, has secured $40m in funding from the Bill & Melinda Gates Foundation to boost its research activities in infectious diseases. The company hopes to develop novel therapeutics to reduce treatment timelines and improve outcomes for patients with HIV and TB.
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.